Influenza Vaccine
Influenza A · Influenza B · Secondary bacterial pneumonia · Influenza encephalitis
Seasonal influenza infects 9–45 million Americans annually and kills 12,000–52,000 per year depending on strain severity. Children under 5, adults over 65, pregnant women, and immunocompromised individuals face the highest risk of severe disease. Flu is not 'just a bad cold' — it can cause viral pneumonia, encephalitis, myocarditis, and bacterial superinfection. The 1918 pandemic killed 50–100 million people.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The risk-benefit balance in your specific scenario suggests a detailed conversation with your child's provider before deciding.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Seasonal influenza infects 9–45 million Americans annually and kills 12,000–52,000 per year depending on strain severity. Children under 5, adults over 65, pregnant women, and immunocompromised individuals face the highest risk of severe disease. Flu is not 'just a bad cold' — it can cause viral pneumonia, encephalitis, myocarditis, and bacterial superinfection. The 1918 pandemic killed 50–100 million people.
Severe flu causes 3–7 days of high fever, body aches, profound fatigue, and respiratory symptoms. Hospitalization rates rise sharply with age. Long COVID-like post-influenza fatigue syndrome exists but is underrecognized. Flu during pregnancy increases risk of premature birth and maternal mortality.
🛡️ Vaccine Effectiveness
Effectiveness varies year to year based on how well the vaccine matches the circulating strains (range: 10–60%). In well-matched years, 50–65% effective against hospitalization. High-dose and adjuvanted formulations are more effective in adults 65+. Protection wanes over the season — ideal timing is late October.
Breakthrough influenza is common due to antigenic mismatch. Vaccinated individuals who get flu typically have milder illness and lower risk of death and hospitalization.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Children 6 months to 8 years receiving flu vaccine for the first time need 2 doses 4 weeks apart in the first season. Annual vaccination recommended for everyone 6 months and older.
⚖️ Benefits vs. Considerations
✓ Benefits
- 80+ years of post-licensure safety data — one of the most studied vaccines in history
- Prevents 12,000–52,000 deaths annually in the US in vaccinated years
- Reduces pediatric flu deaths by ~65% in vaccinated children
- Protects pregnant women and reduces premature birth risk
- Reduces hospitalization and severe disease even in mismatch years
- Annual vaccination reinforces surveillance system that monitors for pandemic strains
↕ Considerations
- Variable effectiveness (10–60%) depending on strain match — can be as low as 10% in poorly matched years
- Does not prevent all flu — breakthrough infections are common
- Annual administration required — can become a burden
- FluMist (nasal) not recommended for immunocompromised or some high-risk groups
- GBS risk: ~1 excess case per million doses (though flu itself causes GBS at higher rate)
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The Cochrane Collaboration's systematic review of influenza vaccine efficacy in healthy adults (Jefferson et al., 2018, 52 trials) found that while NNT (number needed to vaccinate to prevent one flu case) ranged from 40–71 depending on year, the absolute reduction in hospitalization and death was modest in healthy adults — leading some health economists to question whether universal rather than targeted vaccination is the optimal strategy.
- Immune imprinting research (the 'original antigenic sin' hypothesis, updated as 'original antigenic sin' in modern immunology) suggests that early childhood flu vaccinations may shape the immune system's response to novel strains for life — raising questions about whether annual vaccination in very young children affects their long-term influenza immunity architecture (Gostic et al., 2019; PNAS).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Optimal timing within the flu season — too early may result in waning protection before peak season
- Whether universal child vaccination reduces mortality in older adults through herd effects (promising data but not conclusive)
- Universal vs. targeted vaccination cost-effectiveness in countries with limited healthcare budgets
- Long-term impact of annual vaccination on immune imprinting (early childhood exposures may shape lifetime flu immunity in ways that are still being studied)
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.